Similarly, lipid metabolism is disrupted using Orlistat, an FDA-approved obesity drug repurposed to inhibit fatty acid synthase (FASN), thereby halting tumor proliferation and inducing apoptosis in PCa models [344]. Here, FASN is linked to obesity due to melanocortin 4 receptor deficiency.